person · Reporting owner

Van Naarden Jacob

Disclosed activity across 2 companies

Tapewire entity: 11096
SEC CIK: 0001661254

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ELI LILLY & CoLLY · Entity 2794	EVP,Pres LLY Oncology&HdCorpBD	February 09, 2026	February 11, 2026
Loxo Oncology, Inc.LOXO · Entity 160155	Chief Operating Officer	February 15, 2019	February 15, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ELI LILLY & Co

Report date February 09, 2026 · Filed February 11, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	26,626.498	Reported balance After 2026-02-09 transaction · row 1 1 source row Row 1 · 2026-02-09 · Grant · Acquired 4,865.888 · Balance 26,626.498
Common StockSEC Table I · non-derivative	IndirectVan Naarden Family Trust	4,342	Reported balance Holding disclosure · report date 2026-02-09 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 4,342 F1: The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy SLAT	5,302	Reported balance Holding disclosure · report date 2026-02-09 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 5,302 F2: On February 5, 2026, the Reporting Person's spouse transferred 5,302 shares of Eli Lilly and Company common stock to a spousal lifetime access trust, of which the Reporting Person is the trustee and a beneficiary. The transfer included 1,000 spouse-held shares previously reported as directly held due to an administrative error. F1: The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

F2: On February 5, 2026, the Reporting Person's spouse transferred 5,302 shares of Eli Lilly and Company common stock to a spousal lifetime access trust, of which the Reporting Person is the trustee and a beneficiary. The transfer included 1,000 spouse-held shares previously reported as directly held due to an administrative error.

Loxo Oncology, Inc.

Report date February 15, 2019 · Filed February 15, 2019

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2019-02-15 transaction · row 1 1 source row Row 1 · 2019-02-15 · Disposition to issuer · Disposed 19,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.65 · Expires 2024-06-18	Direct	Reported balance After 2019-02-15 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-02-15 · Disposition to issuer · Disposed 35,026 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.67 · Expires 2024-12-18	Direct	Reported balance After 2019-02-15 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-02-15 · Disposition to issuer · Disposed 78,943 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.69 · Expires 2025-12-15	Direct	Reported balance After 2019-02-15 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-02-15 · Disposition to issuer · Disposed 43,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.27 · Expires 2026-12-05	Direct	Reported balance After 2019-02-15 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2019-02-15 · Disposition to issuer · Disposed 74,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.56 · Expires 2027-03-14	Direct	Reported balance After 2019-02-15 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2019-02-15 · Disposition to issuer · Disposed 35,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $84.88 · Expires 2028-01-03	Direct	Reported balance After 2019-02-15 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2019-02-15 · Disposition to issuer · Disposed 200,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $139.77 · Expires 2029-01-01	Direct	Reported balance After 2019-02-15 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2019-02-15 · Disposition to issuer · Disposed 57,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.

F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 14, 2018 Filed May 16, 2018 16:46 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionCommon Stock	1,541	$3.65	$5,621.57	Disclosure SEC source: 0001140361-18-024225 · doc1.xml · nonDerivative · entry 1 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,541 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document
April 25, 2018 Filed Apr 26, 2018 16:32 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	1,541	$0.00 Strike: $3.65	$0.00	Disclosure SEC source: 0001140361-18-019771 · doc1.xml · derivative · entry 12 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,215 Underlying: Common Stock · 1,541 shares Expires 2024-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F10 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on May 12, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document
April 25, 2018 Filed Apr 26, 2018 16:32 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	541	$132.05	$71,441.54	Disclosure SEC source: 0001140361-18-019771 · doc1.xml · nonDerivative · entry 10 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F9 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $131.81 to $132.72 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
April 25, 2018 Filed Apr 26, 2018 16:32 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	600	$130.94	$78,561.00	Disclosure SEC source: 0001140361-18-019771 · doc1.xml · nonDerivative · entry 9 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 541 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F8 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $130.72 to $131.47 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
April 25, 2018 Filed Apr 26, 2018 16:32 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	100	$129.45	$12,945.00	Disclosure SEC source: 0001140361-18-019771 · doc1.xml · nonDerivative · entry 8 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,141 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document
April 25, 2018 Filed Apr 26, 2018 16:32 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	300	$128.72	$38,615.01	Disclosure SEC source: 0001140361-18-019771 · doc1.xml · nonDerivative · entry 7 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,241 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F7 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $128.42 to $128.96 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
April 25, 2018 Filed Apr 26, 2018 16:32 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionCommon Stock	1,541	$3.65	$5,621.57	Disclosure SEC source: 0001140361-18-019771 · doc1.xml · nonDerivative · entry 6 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,541 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document
April 24, 2018 Filed Apr 26, 2018 16:32 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	1,541	$0.00 Strike: $3.65	$0.00	Disclosure SEC source: 0001140361-18-019771 · doc1.xml · derivative · entry 11 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,756 Underlying: Common Stock · 1,541 shares Expires 2024-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F10 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on May 12, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document
April 24, 2018 Filed Apr 26, 2018 16:32 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	500	$133.09	$66,543.00	Disclosure SEC source: 0001140361-18-019771 · doc1.xml · nonDerivative · entry 5 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F6 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $132.60 to $133.48 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
April 24, 2018 Filed Apr 26, 2018 16:32 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	500	$131.88	$65,941.00	Disclosure SEC source: 0001140361-18-019771 · doc1.xml · nonDerivative · entry 4 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F5 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $131.48 to $132.24 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
April 24, 2018 Filed Apr 26, 2018 16:32 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	300	$130.62	$39,185.01	Disclosure SEC source: 0001140361-18-019771 · doc1.xml · nonDerivative · entry 3 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $130.41 to $130.93 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
April 24, 2018 Filed Apr 26, 2018 16:32 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	241	$129.58	$31,229.02	Disclosure SEC source: 0001140361-18-019771 · doc1.xml · nonDerivative · entry 2 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,300 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $129.38 to $129.77 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
April 24, 2018 Filed Apr 26, 2018 16:32 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionCommon Stock	1,541	$3.65	$5,621.57	Disclosure SEC source: 0001140361-18-019771 · doc1.xml · nonDerivative · entry 1 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,541 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document
March 14, 2018 Filed Mar 15, 2018 17:01 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	1,541	$0.00 Strike: $3.65	$0.00	Disclosure SEC source: 0001140361-18-013687 · doc1.xml · derivative · entry 11 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,297 Underlying: Common Stock · 1,541 shares Expires 2024-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F8 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on May 12, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document
March 14, 2018 Filed Mar 15, 2018 17:01 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	646	$132.02	$85,286.66	Disclosure SEC source: 0001140361-18-013687 · doc1.xml · nonDerivative · entry 9 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F7 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $131.58 to $132.31 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
March 14, 2018 Filed Mar 15, 2018 17:01 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	895	$131.05	$117,293.33	Disclosure SEC source: 0001140361-18-013687 · doc1.xml · nonDerivative · entry 8 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 646 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F6 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $130.55 to $131.53 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
March 14, 2018 Filed Mar 15, 2018 17:01 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionCommon Stock	1,541	$3.65	$5,621.57	Disclosure SEC source: 0001140361-18-013687 · doc1.xml · nonDerivative · entry 7 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,541 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document
March 13, 2018 Filed Mar 15, 2018 17:01 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	1,541	$0.00 Strike: $3.65	$0.00	Disclosure SEC source: 0001140361-18-013687 · doc1.xml · derivative · entry 10 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,838 Underlying: Common Stock · 1,541 shares Expires 2024-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F8 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on May 12, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document
March 13, 2018 Filed Mar 15, 2018 17:01 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	100	$134.05	$13,405.00	Disclosure SEC source: 0001140361-18-013687 · doc1.xml · nonDerivative · entry 6 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document
March 13, 2018 Filed Mar 15, 2018 17:01 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	441	$132.48	$58,422.97	Disclosure SEC source: 0001140361-18-013687 · doc1.xml · nonDerivative · entry 5 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F5 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $132.01 to $132.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
March 13, 2018 Filed Mar 15, 2018 17:01 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	400	$131.41	$52,562.00	Disclosure SEC source: 0001140361-18-013687 · doc1.xml · nonDerivative · entry 4 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 541 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $130.87 to $131.71 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
March 13, 2018 Filed Mar 15, 2018 17:01 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	500	$130.28	$65,140.00	Disclosure SEC source: 0001140361-18-013687 · doc1.xml · nonDerivative · entry 3 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 941 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $129.87 to $130.55 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
March 13, 2018 Filed Mar 15, 2018 17:01 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	100	$128.85	$12,885.00	Disclosure SEC source: 0001140361-18-013687 · doc1.xml · nonDerivative · entry 2 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,441 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document
March 13, 2018 Filed Mar 15, 2018 17:01 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionCommon Stock	1,541	$3.65	$5,621.57	Disclosure SEC source: 0001140361-18-013687 · doc1.xml · nonDerivative · entry 1 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,541 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document
February 13, 2018 Filed Feb 14, 2018 17:35 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	1,541	$0.00 Strike: $3.65	$0.00	Disclosure SEC source: 0001140361-18-008379 · doc1.xml · derivative · entry 11 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,379 Underlying: Common Stock · 1,541 shares Expires 2024-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F8 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on May 12, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document
February 13, 2018 Filed Feb 14, 2018 17:35 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	1,041	$101.05	$105,188.37	Disclosure SEC source: 0001140361-18-008379 · doc1.xml · nonDerivative · entry 9 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F7 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $100.57 to $101.44 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
February 13, 2018 Filed Feb 14, 2018 17:35 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	100	$97.87	$9,787.00	Disclosure SEC source: 0001140361-18-008379 · doc1.xml · nonDerivative · entry 8 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,041 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document
February 13, 2018 Filed Feb 14, 2018 17:35 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	100	$96.60	$9,660.00	Disclosure SEC source: 0001140361-18-008379 · doc1.xml · nonDerivative · entry 7 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,141 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document
February 13, 2018 Filed Feb 14, 2018 17:35 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	300	$94.33	$28,299.00	Disclosure SEC source: 0001140361-18-008379 · doc1.xml · nonDerivative · entry 6 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,241 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F6 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $93.91 to $94.66 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
February 13, 2018 Filed Feb 14, 2018 17:35 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionCommon Stock	1,541	$3.65	$5,621.57	Disclosure SEC source: 0001140361-18-008379 · doc1.xml · nonDerivative · entry 5 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,541 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document
February 12, 2018 Filed Feb 14, 2018 17:35 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	1,541	$0.00 Strike: $3.65	$0.00	Disclosure SEC source: 0001140361-18-008379 · doc1.xml · derivative · entry 10 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,920 Underlying: Common Stock · 1,541 shares Expires 2024-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F8 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on May 12, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document
February 12, 2018 Filed Feb 14, 2018 17:35 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	300	$94.49	$28,347.99	Disclosure SEC source: 0001140361-18-008379 · doc1.xml · nonDerivative · entry 4 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F5 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $94.31 to $94.63 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
February 12, 2018 Filed Feb 14, 2018 17:35 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	741	$93.83	$69,524.62	Disclosure SEC source: 0001140361-18-008379 · doc1.xml · nonDerivative · entry 3 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $93.30 to $94.22 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
February 12, 2018 Filed Feb 14, 2018 17:35 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	500	$92.21	$46,105.00	Disclosure SEC source: 0001140361-18-008379 · doc1.xml · nonDerivative · entry 2 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,041 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $91.79 to $92.59 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
February 12, 2018 Filed Feb 14, 2018 17:35 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionCommon Stock	1,541	$3.65	$5,621.57	Disclosure SEC source: 0001140361-18-008379 · doc1.xml · nonDerivative · entry 1 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,541 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document
January 17, 2018 Filed Jan 18, 2018 17:02 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	1,541	$0.00 Strike: $3.65	$0.00	Disclosure SEC source: 0001140361-18-002445 · doc1.xml · derivative · entry 13 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,461 Underlying: Common Stock · 1,541 shares Expires 2024-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F10 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on May 12, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document
January 17, 2018 Filed Jan 18, 2018 17:02 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	200	$89.87	$17,973.00	Disclosure SEC source: 0001140361-18-002445 · doc1.xml · nonDerivative · entry 11 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F9 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $89.82 to $89.91 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
January 17, 2018 Filed Jan 18, 2018 17:02 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	695	$89.23	$62,012.00	Disclosure SEC source: 0001140361-18-002445 · doc1.xml · nonDerivative · entry 10 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F8 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $88.74 to $89.70 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
January 17, 2018 Filed Jan 18, 2018 17:02 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	200	$87.96	$17,592.00	Disclosure SEC source: 0001140361-18-002445 · doc1.xml · nonDerivative · entry 9 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 895 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F7 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $87.48 to $88.44 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
January 17, 2018 Filed Jan 18, 2018 17:02 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	446	$86.30	$38,487.70	Disclosure SEC source: 0001140361-18-002445 · doc1.xml · nonDerivative · entry 8 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,095 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F6 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $86.03 to $86.94 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
January 17, 2018 Filed Jan 18, 2018 17:02 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionCommon Stock	1,541	$3.65	$5,621.57	Disclosure SEC source: 0001140361-18-002445 · doc1.xml · nonDerivative · entry 7 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,541 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document
January 16, 2018 Filed Jan 18, 2018 17:02 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	1,541	$0.00 Strike: $3.65	$0.00	Disclosure SEC source: 0001140361-18-002445 · doc1.xml · derivative · entry 12 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,002 Underlying: Common Stock · 1,541 shares Expires 2024-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F10 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on May 12, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document
January 16, 2018 Filed Jan 18, 2018 17:02 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	100	$90.45	$9,045.00	Disclosure SEC source: 0001140361-18-002445 · doc1.xml · nonDerivative · entry 6 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document
January 16, 2018 Filed Jan 18, 2018 17:02 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	500	$90.07	$45,035.00	Disclosure SEC source: 0001140361-18-002445 · doc1.xml · nonDerivative · entry 5 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F5 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $89.45 to $90.40 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
January 16, 2018 Filed Jan 18, 2018 17:02 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	100	$88.36	$8,836.00	Disclosure SEC source: 0001140361-18-002445 · doc1.xml · nonDerivative · entry 4 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document
January 16, 2018 Filed Jan 18, 2018 17:02 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	200	$87.10	$17,419.00	Disclosure SEC source: 0001140361-18-002445 · doc1.xml · nonDerivative · entry 3 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $87.05 to $87.14 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
January 16, 2018 Filed Jan 18, 2018 17:02 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	SaleCommon Stock	641	$86.53	$55,466.76	Disclosure SEC source: 0001140361-18-002445 · doc1.xml · nonDerivative · entry 2 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $86.05 to $87.04 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document
January 16, 2018 Filed Jan 18, 2018 17:02 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionCommon Stock	1,541	$3.65	$5,621.57	Disclosure SEC source: 0001140361-18-002445 · doc1.xml · nonDerivative · entry 1 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,541 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document
January 04, 2018 Filed Jan 5, 2018 19:09 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	GrantEmployee Stock Option (right to buy) · Derivative	200,000	$0.00 Strike: $84.88	$0.00	Disclosure SEC source: 0001140361-18-001125 · doc1.xml · derivative · entry 1 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2028-01-03 F1 · derivative.exercise_date: 1/24th of the Shares vest the second month anniversary following January 4, 2018 (the "Grant Date"), then an additional 1/48 vest monthly thereafter; provided however, that if the Company has not filed its next Registration Statement on Form S-8 by the first vesting date, then vesting will begin on the date that the Company files its next Registration Statement on Form S-8, but in any event no later than December 31, 2018 (the earlier of such dates, the "Filing Date"), with vesting from the Filing Date calculated based on 1/48th of the Shares per month, measured from the one-month anniversary of the Grant Date. Read SEC document
December 15, 2017 Filed Dec 18, 2017 17:42 UTC	Loxo Oncology, Inc. LOXO · Entity 160155	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	1,541	$0.00 Strike: $3.65	$0.00	Disclosure SEC source: 0001140361-17-046574 · doc1.xml · derivative · entry 11 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,543 Underlying: Common Stock · 1,541 shares Expires 2024-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F9 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on May 12, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.